Spectrum Pharmaceuticals, Inc. (SPPI) stock has risen 14.40% over the past week and gets a Bullish rating from InvestorsObserver’s Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock’s trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver‘s Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What’s Happening With SPPI Stock Today?
Spectrum Pharmaceuticals, Inc. (SPPI) stock is trading at $4.37 as of 1:34 PM on Friday, Jun 11, a loss of -$0.02, or -0.46% from the previous closing price of $4.39. The stock has traded between $4.30 and $4.42 so far today. Volume today is light. So far 956,297 shares have traded compared to average volume of 2,695,835 shares.
More About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.